FY2021 EPS Estimates for Intercept Pharmaceuticals Inc Lifted by Analyst (ICPT)

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Investment analysts at Seaport Global Securities lifted their FY2021 earnings per share estimates for shares of Intercept Pharmaceuticals in a research note issued to investors on Friday. Seaport Global Securities analyst V. Bernardino now expects that the biopharmaceutical company will earn $2.85 per share for the year, up from their prior estimate of $2.76. Seaport Global Securities also issued estimates for Intercept Pharmaceuticals’ FY2022 earnings at $9.65 EPS.

Several other research firms also recently weighed in on ICPT. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Oppenheimer reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 29th. Citigroup set a $74.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, December 29th. Bank of America lowered their price objective on shares of Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating for the company in a research note on Friday, October 13th. Finally, Cowen reaffirmed a “buy” rating and set a $112.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $134.86.

Shares of Intercept Pharmaceuticals (ICPT) opened at $62.87 on Monday. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a market cap of $1,578.17, a price-to-earnings ratio of -4.25 and a beta of -2.13. Intercept Pharmaceuticals has a one year low of $51.53 and a one year high of $135.59.

A number of hedge funds have recently added to or reduced their stakes in the stock. WFG Advisors LP raised its stake in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares in the last quarter. Voya Investment Management LLC raised its stake in Intercept Pharmaceuticals by 4.7% in the second quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock worth $847,000 after buying an additional 313 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Intercept Pharmaceuticals by 23.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 470 shares in the last quarter. Principal Financial Group Inc. raised its stake in Intercept Pharmaceuticals by 3.1% in the second quarter. Principal Financial Group Inc. now owns 15,699 shares of the biopharmaceutical company’s stock worth $1,901,000 after buying an additional 477 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Intercept Pharmaceuticals by 6.2% in the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock worth $1,145,000 after buying an additional 550 shares in the last quarter. 74.37% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “FY2021 EPS Estimates for Intercept Pharmaceuticals Inc Lifted by Analyst (ICPT)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/05/fy2021-eps-estimates-for-intercept-pharmaceuticals-inc-lifted-by-analyst-icpt.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply